Image

Global Patient Derived Xenograft (PDX) Models Market – Industry Trends and Forecast to 2029

  • Healthcare
  • Upcoming Report
  • Mar 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Patient Derived Xenograft (PDX) Models Market, By Type (Mice Models, Rat Models), Tumor Type (Respiratory Tumor Models, Urological Tumor Models, Gastrointestinal Tumor Models, Hematological Tumor Models, Gynecological Tumor Models, Others), Application (Preclinical Drug Development and Oncology Research, Biomarker Analysis), End User (Contract Research Organization, Academic and Research Institutions, Pharmaceutical and Biotechnology Companies) – Industry Trends and Forecast to 2029

Patient Derived Xenograft (PDX) Models Market

Global Patient Derived Xenograft (PDX) Models Market Analysis and Size

Xenograft tumor models are known to preserve original tumor characteristics including, clinical biomolecular signature, tumor archive, heterogeneous histology, and malignant phenotypes and génotypes, among others.

  • The rise in support for cancer research is escalating the growth of patient derived xenograft (PDX) models market. Global Patient Derived Xenograft (PDX) Models Market was valued at USD 142,396.93 million in 2021 and is expected to reach USD 500,362.17 million by 2029, registering a CAGR of 17.01% during the forecast period of 2022-2029.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Type (Mice Models, Rat Models), Tumor Type (Respiratory Tumor Models, Urological Tumor Models, Gastrointestinal Tumor Models, Hematological Tumor Models, Gynecological Tumor Models, Others), Application (Preclinical Drug Development and Oncology Research, Biomarker Analysis), End User (Contract Research Organization, Academic and Research Institutions, Pharmaceutical and Biotechnology Companies)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Market Players Covered

Crown Bioscience Inc. (US), THE JACKSON LABORATORY (US), Champions Oncology, Inc. (US), Charles River Laboratories (US), Wuxi AppTec (China), Oncodesign (Canada), Aragen Bioscience (India), Biocytogen (US), Bioduro (US), Creative Animodel (US), Covance Inc. (US), EPO Berlin-Buch GmbH (Germany), EUROPDX. (Belgium), Explora BioLabs (US), Hera BioLabs (US), Horizon discovery Ltd. (UK), Pharmatest Services (Finland), Urospehere SAS (Cyprus), Xentech (France), Xenopat (France) among others

Market Opportunities

  • Continuous support for cancer research
  • Rise in demand for humanized PDX models
  • Technological development

Global Patient Derived Xenograft (PDX) Models Market Definition

Patient-derived xenografts (PDX) refer to the models of cancer where cells or tissues from a tumor of a patient that are implanted into humanized or immunedeficient mouse. These models are known to simulate human tumor biology that enables natural cancer progression. This provides translational research model in order to evaluate efficacy.

Patient Derived Xenograft (PDX) Models Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints and challenges. All of this is discussed in detail as below:

  • Demand for Personalized Medicine

The increase in demand for personalized medicine across the globe acts as one of the major factors driving the growth of patient derived xenograft (PDX) models market.

  • Continuous Support for Cancer Research

The continuous support for cancer research from the public and private sectors in the form of funds and investments accelerate the market growth.

  • Research and Development

The surge in the number of research and development activities to enhance the treatment options available further influence the market.

Opportunities

Furthermore, rise in demand for humanized PDX models extend profitable opportunities to the market players in the forecast period of 2022 to 2029. Also, technological development will further expand the market.

Restraints/Challenges Global Patient Derived Xenograft (PDX) Models Market

On the other hand, high cost associated with the personalized PDX models and stringent guidelines for the use of animal models in cancer research are expected to obstruct market growth. Also, limitations of PDX models are projected to challenge the patient derived xenograft (PDX) models market in the forecast period of 2022-2029.

This patient derived xenograft (PDX) models market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on patient derived xenograft (PDX) models market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Patient Derived Xenograft (PDX) Models Market

Covid-19 had a negative impact on the patient derived xenograft (PDX) models market owing to the decline in the productivity in life science organizations during the pandemic. The reduction in pharma research and development deals in therapeutic areas, disruption of clinical trials and country-wise lockdowns also impacted the market. The most affected trials were associated with oncology, ID/anti-infectives, cardiovascular disease and respiratory disease. The market will regain its growth the impact of COVID-19 is expected to diminish during the post-pandemic scenario.

Recent Development

  • Collagen Matrix, Inc., a global leader collagen-based, regenerative, xenograft-derived medical devices, and Linden Capital Partners (“Linden”) announced the acquisition of Sunstar’s Degradable Solutions division. It included GUIDOR branded line of resorbable synthetic medical implants. The purpose behind the acquisition is expanding the range of technologies offered to the customers.

Global Patient Derived Xenograft (PDX) Models Market Scope and Market Size

The patient derived xenograft (PDX) models market is segmented on the basis of type, tumor type, application, technique and end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

  • Mice Models
  • Rat Models

On the basis of type, the global patient derived xenograft (PDX) models market is classified into mice models and rat models.

Tumor Type

  • Gastrointestinal Tumor Models
  • Lung Tumor Models
  • Haematological Tumor Models
  • Gynecological Tumor Models
  • Respiratory Tumor Models
  • Urological Tumor Models
  • Others

On the basis of tumor type, the global patient derived xenograft (PDX) models market is classified into gastrointestinal tumor models, lung tumor models, haematological tumor models, gynecological tumor models, respiratory tumor models, urological tumor models and others.

Application

  • Preclinical Drug Development
  • Precision Medicine
  • Co-Clinical Trials
  • Basic Cancer Research

On the basis of application, the global patient derived xenograft (PDX) models market is classified into preclinical drug development, precision medicine, co-clinical trials, and basic cancer research.

Technique

  • Heterotopic Implantation
  • Orthotropic Implantation

On the basis of technique, the global patient derived xenograft (PDX) models market are segmented into heterotopic implantation and orthotropic implantation.

End User

  • Academic and Research Organizations
  • Contract Research Organizations
  • Pharmaceutical and Biotechnological Companies
  • Others

On the basis of end user, the global patient derived xenograft (PDX) models market is segmented into academic and research organizations, contract research organizations, pharmaceutical and biotechnological companies and others.

Patient Derived Xenograft (PDX) Models Market Regional Analysis/Insights

The patient derived xenograft (PDX) models market is analysed and market size insights and trends are provided by country, type, tumor type, application, technique and end user as referenced above.

The countries covered in the patient derived xenograft (PDX)  models market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the patient derived xenograft (PDX) models market because of the increase in the research activity in cancer and stem cells within the region.

Asia-Pacific (APAC) is expected to witness significant growth during the forecast period of 2022 to 2029 due to the rising incidence of cancer in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The patient derived xenograft (PDX) models market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for patient derived xenograft (PDX) models market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the patient derived xenograft (PDX) models market. The data is available for historic period 2010-2020.

Competitive Landscape and Patient Derived Xenograft (PDX) Models Market Share Analysis

The patient derived xenograft (PDX) models market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to patient derived xenograft (PDX) models market.

Some of the major players operating in the patient derived xenograft (PDX) models market are:

  • Crown Bioscience Inc. (US)
  • THE JACKSON LABORATORY (US)
  • Champions Oncology, Inc. (US)
  • Charles River Laboratories (US)
  • Wuxi AppTec (China)
  • Oncodesign (Canada)
  • Aragen Bioscience (India)
  • Biocytogen (US)
  • Bioduro (US)
  • Creative Animodel (US)
  • Covance Inc. (US)
  • EPO Berlin-Buch GmbH (Germany)
  • EUROPDX. (Belgium)
  • Explora BioLabs (US)
  • Hera BioLabs (US)
  • Horizon discovery Ltd. (UK)
  • Pharmatest Services (Finland)
  • Urospehere SAS (Cyprus)
  • Xentech (France)
  • Xenopat (France)

Research Methodology : Global Patient Derived Xenograft (PDX) Models Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=global-pdx-models-market

Customization Available : Global Patient Derived Xenograft (PDX) Models Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions



Frequently Asked Questions

The Patient Derived Xenograft (PDX) Models Market will be projected at USD 500,362.17 million during the forecast period of 2022 to 2029.
The Patient Derived Xenograft (PDX) Models Market is Expected to Witness CAGR of 17.01% During the Forecast Period of 2022 to 2029.
The Major Players Operating in the Patient Derived Xenograft (PDX) Models Market are Crown Bioscience Inc. (US), THE JACKSON LABORATORY (US), Champions Oncology, Inc. (US), Charles River Laboratories (US), Wuxi AppTec (China), Oncodesign (Canada), Aragen Bioscience (India), Biocytogen (US), Bioduro (US), among others.
The Countries Covered in the Patient Derived Xenograft (PDX) Models Market Report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
The Patient Derived Xenograft (PDX) Models Market Report Curated by the Data Bridge Market Research Team Includes In-Depth Expert Analysis, Patient Epidemiology, Pipeline Analysis, Pricing Analysis, and Regulatory Framework.